Beijing Health Guard Biotechnology

Beijing Health Guard Biotechnology (Kangle Weishi) is a leading clinical-stage Chinese biopharmaceutical company dedicated to the research, development, and industrialization of recombinant protein vaccines. The company focuses primarily on high-value vaccine candidates, with its most advanced programs being a trivalent human papillomavirus (HPV) vaccine and a nine-valent HPV vaccine, both in Phase 3 clinical trials. Utilizing a proprietary structural-design-based platform and E. coli-derived virus-like particle (VLP) technology, the company aims to address unmet needs in cervical cancer prevention and other infectious diseases. Founded in 2008 and listed on the Beijing Stock Exchange in 2023, the company is transitioning from a research-focused entity to a commercial-stage organization with a major manufacturing base in Kunming.